financetom
Business
financetom
/
Business
/
Why Quoin Pharmaceuticals (QNRX) Shares Are Nosediving
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Quoin Pharmaceuticals (QNRX) Shares Are Nosediving
Mar 5, 2024 8:10 AM

Quoin Pharmaceuticals Ltd ( QNRX ) – ADR shares are trading lower by 46.9% to $1.54 during Tuesday’s session after the company announced the pricing of a $6.5 million public offering.

The offering consists of ordinary shares, pre-funded warrants, and warrants to purchase additional shares at a combined price of $1.60 per American Depositary Share. The offering includes Series D warrants exercisable immediately and expiring in two years, and Series E warrants expiring in five years.

The closing is expected around March 7, with A.G.P./Alliance Global Partners serving as the sole placement agent. The net proceeds will be utilized for general corporate purposes.

See Also: China’s 2024 Economic Targets Drive Wedge Between Domestic And Offshore Equities

How To Buy QNRX Stock

By now you're likely curious about how to participate in the market for Quoin Pharmaceuticals ( QNRX ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the the case of Quoin Pharmaceuticals ( QNRX ), which is trading at $1.52 as of publishing time, $100 would buy you 65.79 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, QNRX has a 52-week high of $12.00 and a 52-week low of $1.50.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neo Performance Materials Up 15% as it Considers Sale, Other Options, in a Strategic Review
Neo Performance Materials Up 15% as it Considers Sale, Other Options, in a Strategic Review
Jun 14, 2024
01:39 PM EDT, 06/14/2024 (MT Newswires) -- Neo Performance Materials ( NOPMF ) on Friday surged over 15% on last look after launching a strategic review process to boost a share price that has dropped 13% over the past 12 months and could end with the sale of the company. The rare-earths magnets producer said a special board committee will...
Meta Platforms Pauses Data Collection, Meta AI Launch in Europe
Meta Platforms Pauses Data Collection, Meta AI Launch in Europe
Jun 14, 2024
12:40 PM EDT, 06/14/2024 (MT Newswires) -- Meta Platforms ( META ) is pausing training of its large language models using public content shared by adults on Facebook and Instagram across the European Union at the request of Ireland's Data Protection Commission, the regulator said Friday. Meta AI's launch in Europe will be delayed as a result, the company said...
Ocular Therapeutix Shares Rise Following Clinical Development Progress Report
Ocular Therapeutix Shares Rise Following Clinical Development Progress Report
Jun 14, 2024
01:39 PM EDT, 06/14/2024 (MT Newswires) -- Ocular Therapeutix ( OCUL ) shares were up nearly 15% in recent Friday trading after the company reported its clinical development progress at its investor day Thursday. The company said it had enrolled 151 participants in its phase 3 trial evaluating Axpaxli implant against aflibercept injection in patients with wet age-related macular degeneration,...
Sector Update: Consumer
Sector Update: Consumer
Jun 14, 2024
01:31 PM EDT, 06/14/2024 (MT Newswires) -- Consumer stocks were mixed Friday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) increasing 0.1% and the Consumer Discretionary Select Sector SPDR Fund (XLY) down 0.9%. In corporate news, Tesla's (TSLA) investor Vanguard said it voted for Chief Executive Elon Musk's $56 billion pay package Thursday, marking a reversal from its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved